Centrosomal protein 89 promotes the proliferation of neuroblastoma cell lines in vitro

doi:10.16352/j.issn.1001-6325.2026.06.0836

Abstract

Abstract: Objective To explore the function of centrosomal protein 89 (CEP89) in neuroblastoma (NB). Methods The relationship between the expression of CEP89 mRNA and the prognosis of NB patients was clarified through the analysis of three independent primary NB cohorts via Genomics Analysis and Visualization Platform R2. CEP89 protein was examined by immunohistochemical staining in tumors and adjacent tissues from NB patients. CEP89 mRNA in NB cell lines BE(2)-M17,SK-N-BE(2),SH-SY5Y and normal cell lines MCF10A,IMR-90 and hTERT RPE-1 was analyzed by RT-qPCR. Cell lines were transfected with CEP89-targeting siRNA or shRNA. Cell proliferation was detected by crystal violet staining,real time cell analysis (RTCA) and colony formation assays. Cell apoptosis and cell cycle were detected by flow cytometry and cell-cycle analysis. Wound-healing assay was performed to measure cell migration in vitro. Ki67 was analyzed by Western blot and immunofluorescence assay. Results Analysis of R2 database revealed that higher CEP89 expression was associated with poorer survival in NB patients. CEP89 protein expression level was significantly higher in NB patients tumors compared with adjacent tissues. CEP89 showed significantly increased expression at mRNA level in NB cells compared with non-NB normal cells. CEP89 knockdown reduced NB cell viability more significantly compared with normal cells as demonstrated by crystal violet staining,RTCA and colony formation assays. CEP89 knockdown significantly induced apoptosis,limited cell migration,and decreased the expression of Ki67 in NB cells. Conclusions CEP89 expression is significantly increased in NB tumors and NB cells. CEP89 promotes the NB cell proliferation in vitro.

Key words: neuroblastoma, centrosomal protein 89(CEP89), proliferation, migration, apoptosis

CLC Number:

R739.43

GUAN Xiaoxing. Centrosomal protein 89 promotes the proliferation of neuroblastoma cell lines in vitro[J]. Basic & Clinical Medicine, 2026, 46(6): 836-844.

References 15

[1]	Matthay KK,Maris JM,Schleiermacher G,et al. Neuroblastoma[J]. Nat Rev Dis Primers,2016,2:16078-16098.
[2]	Qiu B,Matthay KK. Advancing therapy for neuroblastoma[J]. Nat Rev Clin Oncol,2022,19:515-533.
[3]	Zafar A,Wang W,Liu G,et al. Molecular targeting therapies for neuroblastoma: Progress and challenges[J]. Med Res Rev,2021,41:961-1021.
[4]	van Bon BW,Oortveld MA,Nijtmans LG,et al. CEP89 is required for mitochondrial metabolism and neuronal function in man and fly[J]. Hum Mol Genet,2013,22:3138-3151.
[5]	Tanos BE,Yang HJ,Soni R,et al. Centriole distal appendages promote membrane docking,leading to cilia initiation[J]. Genes Dev,2013,27:163-168.
[6]	Berkel C,Cacan E. Copy number and expression of CEP89,a protein required for ciliogenesis,are increased and predict poor prognosis in patients with ovarian cancer[J]. Cell Biochem Funct,2022,40:298-309.
[7]	贾安娜,郭金鑫,张璇,等. TMEFF1对神经母细胞瘤细胞系增殖的调控[J]. 基础医学与临床,2024,44:637-644.
[8]	张瑶,张璇,贾安娜,等. 嗅素结构域家族蛋白3促进MYCN扩增型神经母细胞瘤细胞系体外增殖[J]. 基础医学与临床,2025,45:168-175.
[9]	Wong SY,Seol AD,So PL,et al. Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis[J]. Nat Med,2009,15:1055-1061.
[10]	Han YG,Kim HJ,Dlugosz AA,et al. Dual and opposing roles of primary cilia in medulloblastoma development[J]. Nat Med,2009,15:1062-1065.
[11]	Fabbri L,Bost F,Mazure NM. Primary cilium in cancer hallmarks[J]. Int J Mol Sci,2019,20:1336-1362.
[12]	Koeniger A,Brichkina A,Nee I,et al. Activation of cilia-independent hedgehog/GLI1 signaling as a novel concept for neuroblastoma therapy[J]. Cancers (Basel),2021,13:1908-1930.
[13]	Luo Y,Ma J,Lu W. The significance of mitochondrial dysfunction in cancer[J]. Int J Mol Sci,2020,21:5598-5621.
[14]	Srinivasan S,Guha M,Dong DW,et al. Disruption of cytochrome c oxidase function induces the Warburg effect and metabolic reprogramming[J]. Oncogene,2016,35:1585-1595.
[15]	Anderson NM,Qin X,Finan JM,et al. Metabolic enzyme DLST promotes tumor aggression and reveals a vulnerabi-lity to OXPHOS inhibition in high-risk neuroblastoma[J]. Cancer Res,2021,81:4417-4430.